Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies (NASDAQ: SINT) reported strategic updates for Q3 2024, highlighting its shift towards the medical device industry. The company ceased its armor division operations, resulting in a $4.5 million impairment charge. Financial highlights include an 18% year-over-year revenue increase and improved liquidity with $4.8 million in cash, up from $3.3 million at end-2023. The company raised $9.4 million year-to-date through strategic offerings. SINTX implemented workforce reductions and is exploring potential mergers, acquisitions, and strategic partnerships while focusing on leveraging its silicon nitride technology in medical applications.
SINTX Technologies (NASDAQ: SINT), an advanced materials company specializing in ceramics, has announced two key executive promotions. Ryan Bock, PhD, has been promoted to Chief Technology Officer (CTO) of SINTX Technologies, while Ann Kutsch has been named President of SINTX Technology Assessment and Transfer (SINTX TA&T), a subsidiary of SINTX.
As CTO, Dr. Bock will lead the strategic development of SINTX's advanced materials technologies and innovation pipeline. Ms. Kutsch will focus on expanding the company's intellectual property portfolio and transitioning key innovations to commercialization. These promotions reflect SINTX's commitment to advancing cutting-edge ceramic technologies for biomedical, aerospace, and industrial applications.
Eric K. Olson, President and CEO of SINTX Technologies, expressed excitement about the promotions, emphasizing the importance of Dr. Bock's and Ms. Kutsch's expertise and vision in advancing the company's mission.
SINTX Technologies and Prodways are jointly hosting a webinar titled 'Innovations in Ceramic Manufacturing: The Role of 3D Printing' on September 24th at 9:00 AM EDT/3:00 PM CEST. The event, organized with TCT Magazine, aims to explore the impact of additive manufacturing on ceramic applications.
The partnership between SINTX and Prodways combines Prodways' 3D printer manufacturing expertise with SINTX's advanced chemical formulations for additive powders and resins. This collaboration focuses on developing Digital Light Processing (DLP) printing for ceramic materials, complementing SINTX's existing expertise in Fused Filament Fabrication (FFF) printing of Silicon Nitride filled filament for biomedical applications.
The webinar will cover insights into how additive manufacturing is transforming ceramic production, innovations in ceramic 3D printing, and discussions on expanding possibilities in industries such as healthcare, aerospace, and defense.
SINTX Technologies (NASDAQ: SINT) has successfully completed its 'at-the-market' (ATM) equity public offering, raising $3.11 million in gross proceeds through the sale of 595,560 shares at an average price of $5.23 per share. The company received net proceeds of $3.05 million, with no warrant coverage provided. As of September 18, 2024, SINTX had 1,342,853 shares outstanding, including the newly sold shares.
The funds will be used for general corporate purposes, including capital expenditures, working capital, potential acquisitions, and other business opportunities. This capital infusion aims to strengthen SINTX's position in ceramic manufacturing innovation, enabling rapid development, prototyping, and large-scale commercialization in aerospace & defense, medical devices, and industrial manufacturing sectors.
SINTX Technologies (NASDAQ: SINT) has received a Notice of Allowance from the USPTO for a patent application covering novel methods of bonding bioactive silicon nitride to zirconia-toughened alumina (ZTA) surfaces. This innovation aims to enhance ZTA's biological properties, improving osseointegration and resistance to bacterial colonization.
The company, the only FDA-registered producer of implantable silicon nitride, has developed a particulate form that can be used in composites and coatings. This allows SINTX to upgrade existing devices and expand silicon nitride's applications to metallic and polymeric substrates.
SINTX's intellectual property portfolio now includes 16 issued U.S. patents and 84 pending worldwide patent applications, reinforcing its position in medical device biomaterial manufacturing.
SINTX Technologies (NASDAQ: SINT) has announced a series of strategic initiatives to strengthen its financial position and enhance long-term growth prospects. The company has raised additional capital through an At-The-Market (ATM) offering and implemented cost-reduction measures expected to result in over 50% reduction in cash used for operating expenses, lowering annual expenses by approximately $5.8 million.
SINTX is also in discussions with lessors to reduce lease obligations by the end of 2024. These measures are expected to extend the company's cash runway well into 2025. CEO Eric K. Olson emphasized the company's commitment to financial discipline while delivering value to stakeholders. SINTX is actively exploring strategic partnerships to enhance its competitive position and drive sustainable growth.
SINTX Technologies (NASDAQ: SINT) has appointed Eric K. Olson as its new Chief Executive Officer and President, succeeding B. Sonny Bal, MD. Dr. Bal will continue as Chairman of the Board. Olson, a serial entrepreneur with over 30 years of experience in medical devices and biomaterials, previously served as CEO during the company's 2014 IPO when it was known as Amedica He most recently founded Foresite Innovations,
The company also designated Gregg Honigblum as Board Advisor. Honigblum, a Managing Director at FNEX Securities, has over 35 years of financial advisory experience and was instrumental in raising SINTX's private equity funding before its IPO. The leadership changes aim to accelerate development and commercialization of SINTX's technologies and enhance shareholder value.
SINTX Technologies (NASDAQ: SINT) announced its Board of Directors initiated a process to explore strategic options for the Company. SINTX specializes in technical materials, with R&D and manufacturing sites in Salt Lake City and Millersville, MD. The company’s product portfolio includes FDA-approved silicon nitride ceramic spinal fusion devices, ceramic-polymer composites, and femoral head technology. SINTX has secured long-term supply agreements in the aerospace sector and has capabilities in 3D printing, CVI and CVD processes, and ballistic materials. CEO Sonny Bal highlighted the need for additional investment to leverage growth opportunities in medical, defense, and renewable energy markets. Ascendiant Capital Markets has been retained as a strategic advisor. No specific outcomes or timelines have been established for this strategic review.
On June 12, 2024, SINTX Technologies announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, as confirmed by a formal notice from Nasdaq on June 11, 2024. This resolution addresses the previous listing issue under Nasdaq Listing Rule 5550(a)(2). Despite this development, SINTX remains under a 'Mandatory Panel Monitor' for one year from June 11, 2024. If the company fails to maintain a $1.00 closing bid price for 30 consecutive business days during this period, Nasdaq will issue a delist determination without a grace period for compliance. The company can request a new hearing if this occurs.
SINTX Technologies, a leader in advanced ceramic materials, has received a $75,000 phase I SBIR contract from AFWERX to enhance the sinterability of 3D printed silicon nitride. This project aims to address material challenges in high-temperature propulsion and guidance systems for the Air Force. If successful, SINTX could secure a phase II contract worth up to $1.25M. This initiative aligns with SINTX's strategic focus on aero-engine and RF applications. The company leverages its expertise in silicon nitride and the additive manufacturing knowledge of its subsidiary, TA&T, acquired in 2022. This effort underscores SINTX's broader technical ceramics market expansion, including aerospace and defense sectors.